Articoli - IVAS

Articoli

Articoli

The SaRePo protocol: A seven-step strategy to minimize complications potentially related to the removal of totally implanted central venous access devices

/in News /da grafica

Clicca Qui per leggere l’articolo

An Italian expert consensus on the choice of the method of tip location for central venous access devices

/in News /da grafica

Clicca Qui per leggere l’articolo

International experts consensus on optimal central vascular access device selection and management for patients with cancer

/in News /da grafica

Clicca Qui per leggere l’articolo

Articoli precedenti

Position statement GAVeCeLT-IVAS sulla appropriatezza dell’impianto di sistemi venosi centrali totalmente impiantabili (port) da parte del personale infermieristico

A GAVeCeLT consensus on the indication, insertion, and management of central venous access devices in the critically ill

IVAS informa

Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)

PICC‑related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count

Leukemia & Lymphoma

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES

Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients

Qualitative interviews and supporting evidence to identify the positive impacts of multidisciplinary vascular access teams

Rassegna stampa Accessi Vascolari nei pazienti Covid-19

L’Accesso Vascolare nel paziente COVID-19

COVID-19 Guida Medica Clinico-Pratica

Comunicazione COVID-19

Protocollo operativo: Accessi venosi ecoguidati in ambiente protetto e a domicilio: impianto e gestione.

Lettera Aiom

Can Peripherally Inserted Central Catheters Be Safely Placed in Patients with Cancer Receiving Chemotherapy? A Retrospective Study of Almost 400,000 Catheter-Days

Can Peripherally Inserted Central Catheters Be Safely Placed in Patients with Cancer Receiving Chemotherapy? A Retrospective Study of Almost 400,000 Catheter‐Days

Leapfrog Group: Rate of serious, even fatal, hospital infections still too high

CVC compra DOC Generici da Charterhouse. Che porta a casa un Irr del 40%

Entra anche tu a far parte di IVAS!

CEC comunicazione eventi congressi srl

Via Canton, 101 00144, Roma

email: info@cecongressi.it – tel: 06 60210 638